Cargando…
ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma
Background: Treatment intervention for central nervous system lymphoma (CNSL) requires pathological diagnosis by surgical biopsy. However, there are some cases in which the risk of surgery is high due to age, comorbidities, localization of lesions, etc. We are developing a CNSL diagnostic method bas...
Autores principales: | Yuki, Yamagishi, Sasaki, Nobuyoshi, Matsushita, Yuko, Shimizu, Saki, Matsumoto, Yoshie, Saito, Kuniaki, Kobayashi, Keiichi, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Ichimura, Koichi, Nagane, Motoo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664634/ http://dx.doi.org/10.1093/noajnl/vdab159.088 |
Ejemplares similares
-
ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid
por: Yamagishi, Yuki, et al.
Publicado: (2020) -
Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021) -
ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020) -
ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021) -
NQPC-21 QOL EVALUATION IN THE TREATMENT COURSE OF CNS LYMPHOMA
por: Yamagishi, Yuki, et al.
Publicado: (2022)